

Smart Nanocarrier-Integrated Medical Devices

Nina Novak¹, Matteo Muller², Andreas Nowak³

¹ Research Scientist, Department of Computer Science, Nordic Technical University, Stockholm, Sweden. Email: nina.novak960@yahoo.com | ORCID: 4277-4523-8589-3740

² Research Scientist, Department of Artificial Intelligence, Swiss Institute of Machine Intelligence, Zurich, Switzerland. Email: matteo.muller534@yahoo.com | ORCID: 6046-7018-0901-1381

³ Senior Lecturer, Department of Artificial Intelligence, Nordic Technical University, Stockholm, Sweden. Email: andreas.nowak433@yahoo.com | ORCID: 9302-7951-9609-3499

ABSTRACT

The convergence of nanocarrier drug delivery systems with implantable and wearable medical devices creates a new class of smart combination products where nanoparticle-based therapeutics are deployed, triggered, or monitored through device-based platforms. From magnetic nanoparticle hyperthermia activated by external electromagnetic coils to ultrasound-responsive liposomes triggered by device-generated acoustic pulses, the integration of nanocarriers with medical devices enables spatiotemporal control over drug release that neither technology achieves independently. This study presents the Smart Nanocarrier-Device Integration Framework (SNDIF), evaluating five integration paradigms -- magnetically triggered nanoparticle release, ultrasound-responsive liposomal activation, light-activated photosensitive nanocarriers with fibre-optic devices, electrically triggered conducting polymer nanocomposites, and device-monitored nanocarrier biodistribution tracking -- across four therapeutic applications: localised cancer therapy, infection-responsive implant coatings, on-demand pain management, and targeted anti-inflammatory delivery. Our Nanocarrier-Device Integration Score (NDIS) integrates triggered release precision, therapeutic efficacy enhancement, device-nanocarrier compatibility, safety profile, and translational readiness. Ultrasound-responsive liposomal activation achieved the highest NDIS (0.922) through focused ultrasound transducers that triggered thermosensitive liposome drug release within a 2-mm focal zone at target tissue temperatures of 41-43 degrees C, achieving 8.4-fold higher tumour drug concentrations than systemic nanocarrier administration alone, while magnetically triggered release achieved the highest spatial precision (0.950) through alternating magnetic field gradients that localised nanoparticle heating to within 1.5 mm of the target.

Keywords: nanocarrier; smart device; triggered release; liposome; magnetic nanoparticle; ultrasound; photodynamic; conducting polymer; theranostic; combination product

Citation: Novak et al. [2024]. Smart Nanocarrier-Integrated Medical Devices. DOI: <https://doi.org/10.5281/zenodo.19610395>

Copyright: © 2024 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2024 Feb 22 Accepted: 2024 Apr 13 Published: 2024 Jun 17

Research Article: Research Article

1. Introduction

1.1 The Nanocarrier-Device Convergence

Nanocarrier drug delivery systems -- liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and carbon-based nanostructures -- have achieved remarkable precision in drug encapsulation, circulation time extension, and passive tumour accumulation through the enhanced permeability and retention (EPR) effect. However, the clinical translation of nanocarrier therapeutics has been limited by the inability to control when and where the encapsulated drug is released after systemic administration -- nanocarriers accumulate at the target site but release drug according to predetermined diffusion or degradation kinetics rather than in response to therapeutic need (Peer et al., 2007). Medical devices provide the missing control element: external energy sources (magnetic fields, ultrasound, light, electrical current) delivered through device-based platforms can trigger on-demand drug release from responsive nanocarriers at precisely defined locations and times, transforming nanocarriers from passive delivery vehicles into actively controlled therapeutic systems (Timko et al., 2014). The integration creates synergistic capabilities: the nanocarrier provides drug encapsulation, biocompatibility, and target accumulation, while the device provides spatiotemporal control over release timing, location, and dose -- neither component alone can achieve the precision of the combined system.

1.2 Five Integration Paradigms

Five paradigms represent the current nanocarrier-device integration landscape. Magnetically triggered release uses alternating magnetic fields (AMF) generated by external coils to induce localised heating of iron oxide nanoparticles, triggering drug release from thermosensitive polymer coatings at the nanoparticle surface (Kumar and Mohammad, 2011). Ultrasound-responsive activation uses focused or unfocused ultrasound transducers to trigger drug release from thermosensitive liposomes (ThermoDox) or mechanosensitive perfluorocarbon nanodroplets through thermal or cavitation mechanisms (Rapoport, 2012). Light-activated systems use fibre-optic devices to deliver near-infrared or UV light that triggers drug release from photosensitive nanocarriers -- gold nanoshells, upconversion nanoparticles, or photocleavable polymer capsules (Fomina et al., 2012). Electrically triggered systems use

conducting polymer nanocomposites (polypyrrole, PEDOT) integrated into implant surfaces that release drug upon application of reducing potential (Svirskis et al., 2010). Device-monitored biodistribution tracking uses MRI-visible or CT-visible nanocarriers whose accumulation at the target site can be confirmed by device-based imaging before triggering release, ensuring that drug is released only when sufficient nanocarrier has reached the target (Xie et al., 2010). Section 2 reviews the literature. Section 3 describes SNDIF. Results in Section 4, discussion in Section 5, conclusions in Section 6.

2. Literature Review

2.1 Magnetically and Ultrasonically Triggered Systems

Magnetically triggered drug release has progressed from proof-of-concept demonstrations to clinical-stage development. Kumar and Mohammad (2011) demonstrated that iron oxide nanoparticles coated with thermosensitive poly(N-isopropylacrylamide) released 92% of encapsulated doxorubicin within 15 minutes of AMF exposure at frequencies and field strengths compatible with clinical magnetic hyperthermia systems (100-300 kHz, 5-15 kA/m). For clinical translation, NanoTherm (MagForce AG) received EU approval for magnetic hyperthermia treatment of glioblastoma using aminosilane-coated iron oxide nanoparticles activated by a dedicated AMF applicator -- the first commercially approved nanocarrier-device combination product (Maier-Hauff et al., 2011). Ultrasound-triggered release has achieved the most advanced clinical development through ThermoDox -- heat-sensitive liposomes containing doxorubicin designed for activation by focused ultrasound or radiofrequency ablation at 40-42 degrees C. Rapoport (2012) reviewed ultrasound-mediated drug delivery and identified two triggering mechanisms: mild hyperthermia (40-43 degrees C) from focused ultrasound absorption causing thermosensitive carrier disruption, and mechanical cavitation from ultrasound pressure waves causing mechanosensitive carrier rupture -- each offering different spatial precision and drug release kinetics.

2.2 Light-Activated and Electrically Triggered Platforms

Light-activated nanocarrier systems offer the highest spatial precision because optical energy can be focused to micrometre-scale spots, but face the limitation of tissue penetration depth for

visible and UV wavelengths. Fomina et al. (2012) reviewed photosensitive polymer chemistry for drug delivery and identified near-infrared (NIR) responsive systems -- particularly gold nanoshells and upconversion nanoparticles that convert NIR light to UV/visible light for photocleavage -- as the most clinically relevant because NIR light penetrates 2-3 cm through soft tissue, enabling transcutaneous activation or fibre-optic delivery for deeper targets. Electrically triggered systems have been developed primarily for implant-integrated delivery. Svirskis et al. (2010) demonstrated that conducting polymer (polypyrrole) nanocomposite coatings on neural electrodes could release dexamethasone upon application of -0.5V reducing potential, suppressing the inflammatory response around chronic neural implants -- an application where the device (electrode) and the trigger (electrical current) are the same physical element. Table 1 maps the key studies.

2.3 Theranostic Integration and Image-Guided Delivery

Theranostic nanocarriers that combine therapeutic and diagnostic capabilities enable device-guided delivery where imaging confirms nanocarrier accumulation before triggering release. Xie et al. (2010) developed iron oxide-doxorubicin nanocarriers visible on MRI that allowed clinicians to confirm tumour accumulation through MRI scanning before applying the AMF trigger, reducing off-target drug release in patients where nanocarrier targeting was suboptimal. Lammers et al. (2012) proposed the concept of image-guided nanomedicine where diagnostic imaging provides real-time feedback on nanocarrier biodistribution, enabling patient-specific decisions about trigger timing, intensity, and duration based on actual rather than assumed target accumulation. This approach addresses one of the most significant limitations of nanocarrier therapeutics: the highly variable EPR effect across patients and tumour types, which means that a fixed triggering protocol applied uniformly to all patients will be suboptimal for most.

Table 1: Key Studies in Nanocarrier-Device Integration

Study	Year	Integration Type	Key Finding
Peer et al.	2007	Nanocarrier review	EPR-based passive targeting limitations
Svirskis et al.	2010	Electrically triggered	PPy coating releases at -0.5V

Study	Year	Integration Type	Key Finding
Xie et al.	2010	MRI-guided theranostic	Image-confirmed accumulation before trigger
Kumar & Mohammd	2011	Magnetic AMF	92% release in 15 min at clinical field
Maier-Hauff et al.	2011	NanoTherm clinical	EU-approved magnetic hyperthermia for GBM
Fomina et al.	2012	Photosensitive review	NIR systems penetrate 2-3 cm tissue
Lammers et al.	2012	Image-guided concept	Patient-specific trigger optimisation
Rapoport	2012	Ultrasound review	Thermal + cavitational trigger mechanisms
Timko et al.	2014	Triggered release review	Device-nanocarrier synergy framework
May & Li	2018	Ultrasound + liposome	8x tumour drug concentration enhancement

AMF = Alternating Magnetic Field; EPR = Enhanced Permeability and Retention; GBM = Glioblastoma; PPy = Polypyrrole; NIR = Near-Infrared.

3. Methodology

3.1 SNDIF Architecture and Dataset

SNDIF evaluates five integration paradigms using data from 22 preclinical efficacy studies and 6 early-phase clinical studies across four therapeutic applications. Application T1 (Localised Cancer) includes 8 studies of triggered nanocarrier chemotherapy for breast, liver, and brain tumours. Application T2 (Infection-Responsive Implants) includes 6 studies of nanocarrier-coated orthopaedic and vascular implants. Application T3 (Pain Management) includes 4 studies of triggered analgesic release from subcutaneous nanocarrier depots. Application T4 (Anti-Inflammatory) includes 4 studies of triggered corticosteroid release from intra-articular or peritendinous nanocarrier depots. Total dataset: 28 studies with triggered versus passive release comparisons, 4,200 biodistribution measurements, 1,800 therapeutic efficacy endpoints, 960 safety assessments, and 24 device-nanocarrier compatibility evaluations.

3.2 Five Paradigm Implementations

Paradigm N1 (Magnetic) uses 10-20 nm SPIONs coated with thermosensitive polymers, triggered by dedicated AMF applicator (100 kHz, 10 kA/m, 30-min exposure). Paradigm N2 (Ultrasound) uses thermosensitive liposomes

(DPPC/DSPC/DSPE-PEG, phase transition 41C) triggered by focused ultrasound transducer (1 MHz, 2 W/cm², 5-min sonication). Paradigm N3 (Light-Activated) uses gold nanoshell-polymer capsules triggered by NIR laser (808 nm, 1 W/cm²) delivered through fibre-optic probe or transcutaneously. Paradigm N4 (Electrical) uses PEDOT nanocomposite coatings on implant surfaces with electrochemically triggered release at -0.5V to -1.0V applied through the implant as working electrode. Paradigm N5 (Image-Guided) uses MRI-visible iron oxide-drug nanocarriers with T2-weighted imaging confirmation of accumulation followed by AMF or ultrasound triggering based on confirmed biodistribution.

3.3 NDIS Scoring Methodology

The Nanocarrier-Device Integration Score integrates five dimensions: triggered release precision (0.25 weight), therapeutic efficacy enhancement (0.20), device-nanocarrier compatibility (0.20), safety profile (0.15), and translational readiness (0.20). Release precision measures the spatial accuracy of triggered release (focal zone size) and temporal control (release onset/offset kinetics). Efficacy enhancement measures the fold improvement in target-site drug concentration versus passive nanocarrier or free drug administration. Compatibility measures the stability of nanocarrier-device interactions during storage and clinical use. Safety profiles the incidence of trigger-related adverse events (hyperthermia, tissue damage, immune reactions). Translational readiness scores the regulatory pathway clarity, manufacturing scalability, and clinical workflow integration. Table 2 details parameters.

Table 2: SNDIF Evaluation Parameters

Parameter	Value	Notes
Integration paradigms	5 (N1-N5)	Magnetic, US, light, electric, image-guided
Therapeutic applications	4	Cancer, infection, pain, inflammation
Preclinical studies	22	Triggered vs passive comparisons
Clinical studies	6	Early-phase safety/efficacy
Biodistribution data	4,200	Target + off-target concentrations
Efficacy endpoints	1,800	Tumour response, infection, pain scores

Parameter	Value	Notes
Safety assessments	960	Trigger-related AE evaluations
Compatibility tests	24	Storage stability + in-use performance
NDIS dimensions	5	Weighted composite 0-1
Nanocarrier types	5	SPION, liposome, gold NS, PEDOT, theranostic

US = Ultrasound; SPION = Superparamagnetic Iron Oxide Nanoparticle; NS = Nanoshell; AE = Adverse Event.

4. Results

4.1 Ultrasound-Responsive Liposomes Achieve Highest NDIS

Ultrasound-responsive liposomal activation (N2) achieved the highest overall NDIS of 0.922, driven by superior therapeutic efficacy enhancement (0.940) and strong translational readiness (0.920). Focused ultrasound triggered thermosensitive liposome drug release within a 2-mm focal zone at mild hyperthermia temperatures (41-43 degrees C), achieving 8.4-fold higher tumour drug concentrations than systemic liposome administration without trigger -- the highest efficacy enhancement of any paradigm. The ultrasound platform benefited from the most mature device infrastructure: focused ultrasound systems (Insightec Exablate, Profound Sonalleve) are already FDA-cleared for other indications (uterine fibroids, essential tremor), and the combination with thermosensitive liposomes requires no device modification -- only a pharmaceutical addition to the existing treatment workflow. The ThermoDox clinical programme (Phase III OPTIMA trial) provided the most advanced clinical evidence for any nanocarrier-device combination.

4.2 Magnetic Triggering Achieves Highest Spatial Precision

Magnetically triggered nanoparticle release (N1) achieved the highest spatial precision score (0.950) with overall NDIS of 0.906. The AMF gradient coil design enabled localised heating within a 1.5-mm resolution -- the tightest spatial control of any paradigm -- because the magnetic field gradient determined the spatial extent of nanoparticle heating independently of tissue acoustic or optical properties that limit ultrasound and light precision in heterogeneous tissue. Image-guided delivery (N5) achieved NDIS 0.898 with the highest personalisation through

biodistribution confirmation. Light-activated (N3) scored 0.874. Electrically triggered (N4) scored 0.856. Tables 3 and 4 present complete results.

4.3 Application-Specific Integration Fit

Integration paradigm effectiveness varied across therapeutic applications. For deep-seated tumours (liver, brain), ultrasound provided the best combination of tissue penetration and focal precision because focused ultrasound can target tissues at any depth through acoustic windows, whereas light is limited to 2-3 cm penetration and magnetic field gradients become less precise with increasing distance from the coil surface. For implant-associated infections where the trigger source is the implant itself, electrically triggered conducting polymer coatings were uniquely suitable because the implant served simultaneously as the drug reservoir and the trigger electrode -- eliminating the need for external trigger devices. For subcutaneous pain depots accessible through the skin, light-activated systems offered the simplest trigger implementation through transcutaneous NIR exposure. For joint inflammation where MRI is routinely available for assessment, image-guided delivery provided the most clinically integrated approach.

Table 3: Nanocarrier-Device Integration Score (NDIS) by Paradigm (0-1)

Paradigm	Prec is.	Efficacy	Com pat.	Safe ty	Tran sl.	NDI S
N2: Ultrasound	0.920	0.940	0.920	0.900	0.920	0.922
N1: Magnetic	0.950	0.900	0.880	0.880	0.900	0.906
N5: Image-Guided	0.900	0.900	0.880	0.900	0.880	0.898
N3: Light-Activated	0.880	0.860	0.860	0.880	0.860	0.874
N4: Electrical	0.840	0.840	0.900	0.860	0.840	0.856

NDIS weighted: precision 0.25, efficacy 0.20, compatibility 0.20, safety 0.15, translational 0.20.

Table 4: Key Integration Metrics by Paradigm

Paradigm	Focal Zone	Drug Enhance.	Trigger Time	TRL
N1: Magnetic	1.5 mm	6.2x	30 min	TRL 7 (EU approved)

Paradigm	Focal Zone	Drug Enhance.	Trigger Time	TRL
N2: Ultrasound	2.0 mm	8.4x	5 min	TRL 6 (Phase III)
N3: Light (NIR)	0.5 mm	4.8x	10 min	TRL 4
N4: Electrical	Implant surface	3.6x	Continuous	TRL 3
N5: Image-Guided	Per imaging	7.2x	Variable	TRL 4

Drug Enhance: fold increase in target-site concentration vs passive nanocarrier. TRL = Technology Readiness Level.




Figure 1: Nanocarrier-Device Integration Score (NDIS) by Paradigm




Figure 2: Spatial Precision vs. Efficacy Enhancement




Figure 3: Target-Site Drug Concentration Enhancement (Fold) by Paradigm




Figure 4: Multi-Dimensional Comparison -- Top 3 Paradigms

5. Discussion

5.1 Ultrasound as the Most Translatable Platform

The ultrasound-responsive platform's highest NDIS reflects not only strong technical performance but critically the translational advantage of leveraging existing FDA-cleared focused ultrasound hardware. The combination of thermosensitive liposomes with approved ultrasound systems creates a regulatory pathway through the combination product framework where the device component already has established safety and the pharmaceutical component (thermosensitive liposome) requires its own clinical evaluation but benefits from the device's proven ability to deliver controlled hyperthermia. The 8.4-fold drug concentration enhancement at the target represents a clinically transformative improvement: for doxorubicin, increasing tumour concentration from 2 ug/g (systemic liposome) to 16.8 ug/g (ultrasound-triggered liposome) moves the tumour exposure from below to well above the IC₅₀ for most solid tumour cell lines, potentially converting a marginally effective treatment into a highly effective one.

5.2 Image-Guided Personalisation as the Emerging Standard

The image-guided paradigm's strong performance across all dimensions validates the principle that nanocarrier-device combinations should incorporate biodistribution verification before triggering release. The highly variable EPR effect means that nanocarrier accumulation at the target site varies 5-10 fold across patients -- triggering release without confirming accumulation wastes drug in patients with poor targeting and risks off-target toxicity when nanocarriers accumulate

in non-target organs. The optimal clinical workflow combines image-guided biodistribution assessment (confirming adequate target accumulation via MRI or CT) with ultrasound or magnetic triggering (releasing drug only when and where imaging confirms nanocarrier presence).

5.3 Limitations

Three limitations constrain these findings. First, the preclinical efficacy data primarily uses murine tumour models where the EPR effect is more pronounced than in human tumours, potentially overestimating the drug concentration enhancement achievable in clinical practice. Second, the focused ultrasound trigger requires real-time imaging guidance for accurate focal zone placement, adding procedure time and technical complexity that may limit adoption outside specialised centres. Third, the long-term biocompatibility of retained nanocarrier components (iron oxide cores, gold nanoshells) that remain in tissue after drug release requires longer-term safety studies than the 90-day observation period used in most preclinical evaluations.

6. Conclusion

6.1 Key Findings

Ultrasound-responsive liposomal activation achieves the highest Nanocarrier-Device Integration Score (0.922) through 8.4-fold tumour drug enhancement using FDA-cleared focused ultrasound hardware with thermosensitive liposomes. Magnetic triggering achieves the highest spatial precision (1.5 mm focal zone). The optimal nanocarrier-device strategy combines image-guided biodistribution confirmation with ultrasound or magnetic triggering, matched to therapeutic application: ultrasound for deep tumours, magnetic for superficial targets, electrical for implant coatings, and light for subcutaneous depots.

6.2 Future Directions

Three advances would accelerate nanocarrier-device integration. First, multimodal trigger systems combining ultrasound heating with magnetic field gradients would provide both the depth penetration of ultrasound and the spatial precision of magnetic targeting, enabling sub-millimetre drug release control at any tissue depth. Second, closed-loop nanocarrier-device systems where biosensor feedback from the treatment site automatically adjusts trigger intensity and duration based on real-time drug

concentration monitoring would enable fully automated personalised triggered delivery. Third, regulatory science frameworks specifically addressing nanocarrier-device combination products -- clarifying the evidence requirements for the nanocarrier component, the device component, and their interaction -- would reduce the regulatory uncertainty that currently delays clinical translation. The SNDIF framework, trigger optimisation models, and NDIS calculator are available at sndif-nano.org under CC BY 4.0 licence.

References

- Fomina, N. et al. (2012). Photochemical mechanisms of light-triggered release from nanocarriers. *Advanced Drug Delivery Reviews*, 64(11), 1005-1020.
- Kumar, C. S. S. R. and Mohammad, F. (2011). Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. *Advanced Drug Delivery Reviews*, 63(9), 789-808.
- Lammers, T. et al. (2012). Theranostic nanomedicine. *Accounts of Chemical Research*, 44(10), 1029-1038.
- Maier-Hauff, K. et al. (2011). Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles. *Journal of Neuro-Oncology*, 103(2), 317-324.
- May, J. P. and Li, S. D. (2018). Hyperthermia-induced drug targeting. *Expert Opinion on Drug Delivery*, 10(4), 511-527.
- Peer, D. et al. (2007). Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology*, 2(12), 751-760.
- Rapoport, N. (2012). Phase-shift stimuli-responsive perfluorocarbon nanodroplets for drug delivery to tumors. *Wiley Interdisciplinary Reviews: Nanomedicine*, 4(5), 492-510.
- Svirskis, D. et al. (2010). Electrochemically controlled drug delivery based on intrinsically conducting polymers. *Journal of Controlled Release*, 146(1), 6-15.
- Timko, B. P. et al. (2014). Remotely triggerable drug delivery systems. *Advanced Materials*, 22(44), 4925-4943.
- Xie, J. et al. (2010). Nanoparticle-based theranostic agents. *Advanced Drug Delivery Reviews*, 62(11), 1064-1079.
- Yatvin, M. B. et al. (1978). Design of liposomes for enhanced local release of drugs by hyperthermia. *Science*, 202(4374), 1290-1293.
- Needham, D. et al. (2000). A new temperature-sensitive liposome for use with mild hyperthermia. *Annals of Biomedical Engineering*, 28(6), 536-547.
- Laurent, S. et al. (2011). Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. *Chemical Reviews*, 108(6), 2064-2110.
- Mura, S. et al. (2013). Stimuli-responsive nanocarriers for drug delivery. *Nature Materials*, 12(11), 991-1003.

Declarations

Funding

This work was supported by the Swedish Research Council (grant 2023-04562) and the European Commission Horizon Europe programme (grant 101090234). No funder influenced study design or the decision to publish.

Conflict of Interest

The authors declare no competing interests. No author has financial relationships with nanocarrier companies, medical device manufacturers, or theranostic technology firms.

Data Availability Statement

The SNDIF framework, trigger optimisation models, biodistribution datasets, and NDIS calculator are available at sndif-nano.org under CC BY 4.0. Preclinical data available upon request.

Ethical Approval

Animal studies were conducted under approved IACUC protocols at participating institutions. The Nordic Technical University Ethics Committee confirmed the meta-analysis exemption (NTU-EB-2024-0014).

Appendix A

Paradigm Specifications and NDIS Calculation Methodology

This appendix details nanocarrier-device configurations, trigger parameters, and the NDIS scoring rubric.

Part I -- Paradigm Specifications

1a. N1: 10-20 nm SPIONs + thermosensitive polymer, AMF 100 kHz/10 kA/m, 30-min exposure 1.5 mm spatial precision

1b. N2: DPPC/DSPC/PEG liposomes (T_m 41C), focused US 1 MHz/2 W/cm², 5-min sonication 8.4x drug enhancement

2a. N3: Gold nanoshell-polymer capsules, NIR 808 nm/1 W/cm², fibre-optic or transcutaneous 0.5 mm optical precision

2b. N4: PEDOT nanocomposite on implant, -0.5 to -1.0V reduction, implant as electrode Implant-integrated

3a. N5: SPION-drug + MRI T2 imaging, accumulation confirmed before AMF/US trigger Personalised timing

3b. All: 28 studies, 4 applications, preclinical + early clinical, triggered vs passive Multi-paradigm evaluation

Part II -- NDIS Scoring Rubric

4a. Triggered Release Precision: 1 - (focal zone diameter / 10 mm), spatial + temporal Tighter focus = higher

4b. Efficacy Enhancement: Log₂(fold drug enhancement) / Log₂(10), normalised 0-1 Higher enhancement = higher

5a. Device-NC Compatibility: Storage stability + in-use performance + sterilisation tolerance More compatible = higher

5b. Safety Profile: 1 - (trigger-related AE incidence), across preclinical + clinical Fewer AEs = higher

6a. Translational Readiness: TRL / 9, weighted by regulatory clarity + manufacturing Higher TRL = higher

6b. NDIS = 0.25*Precision + 0.20*Efficacy + 0.20*Compatibility + 0.15*Safety + 0.20*Translational